npj Breast Cancer (Jan 2025)
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes
- Fresia Pareja,
- Rohit Bhargava,
- Virginia F. Borges,
- Edi Brogi,
- Rita Canas Marques,
- Fatima Cardoso,
- Christine Desmedt,
- Malini Harigopal,
- Sunil R. Lakhani,
- Adrian Lee,
- Jose Pablo Leone,
- Hannah Linden,
- Christopher J. Lord,
- Caterina Marchio,
- Sofia D. Merajver,
- Emad Rakha,
- Jorge S. Reis-Filho,
- Andrea Richardson,
- Elinor Sawyer,
- Pepper Schedin,
- Christopher J. Schwartz,
- Andrew Tutt,
- Naoto T. Ueno,
- Anne Vincent-Salomon,
- Britta Weigelt,
- Y. Hannah Wen,
- Stuart J. Schnitt,
- Steffi Oesterreich
Affiliations
- Fresia Pareja
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
- Rohit Bhargava
- Department of Pathology, University of Pittsburgh School of Medicine, UPMC Magee-Womens Hospital
- Virginia F. Borges
- Division of Medical Oncology, University of Colorado Anschutz Medical Campus
- Edi Brogi
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
- Rita Canas Marques
- Department of Pathology, Champalimaud Foundation
- Fatima Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation
- Christine Desmedt
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven
- Malini Harigopal
- Department of Pathology, Icahn School of Medicine at Mount Sinai
- Sunil R. Lakhani
- UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, and Pathology Queensland
- Adrian Lee
- Women’s Cancer Research Center, Magee-Womens Research Institute, UPMC Hillmann Cancer Center
- Jose Pablo Leone
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Hannah Linden
- Division of Hematology and Oncology, Fred Hutchinson Cancer Center/University of Washington
- Christopher J. Lord
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Caterina Marchio
- Candiolo Cancer Institute, FPO - IRCCS, Candiolo
- Sofia D. Merajver
- Breast and Ovarian Cancer Risk Evaluation Program, Department of Internal Medicine, Michigan Medicine
- Emad Rakha
- Department of Pathology, School of Medicine, University of Nottingham and Nottingham University Hospitals NHS Trust
- Jorge S. Reis-Filho
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
- Andrea Richardson
- Department of Pathology, John Hopkins Medicine
- Elinor Sawyer
- School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy’s Cancer Centre, King’s College London
- Pepper Schedin
- Knight Cancer Institute, Oregon Health & Science University
- Christopher J. Schwartz
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
- Andrew Tutt
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Naoto T. Ueno
- Breast Medical Oncology, University of Hawaii Cancer Center
- Anne Vincent-Salomon
- Department of Pathology, Curie Institute, Paris Sciences Lettres University
- Britta Weigelt
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
- Y. Hannah Wen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
- Stuart J. Schnitt
- Department of Pathology, Brigham and Women’s Hospital
- Steffi Oesterreich
- Women’s Cancer Research Center, Magee-Womens Research Institute, UPMC Hillmann Cancer Center
- DOI
- https://doi.org/10.1038/s41523-025-00719-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
Abstract Special histologic subtypes of breast cancer (BC) exhibit unique phenotypes and molecular profiles with diagnostic and therapeutic implications, often differing in behavior and clinical trajectory from common BC forms. Novel methodologies, such as artificial intelligence may improve classification. Genetic predisposition plays roles in a subset of cases. Uncommon BC presentations like male, inflammatory and pregnancy-related BC pose challenges. Emerging therapeutic strategies targeting genetic alterations or immune microenvironment are being explored.
